The application leverages existing clinical data for Uzedy along with prior FDA findings on the safety of Udezy in patients ...

Kepler Capital analyst Nicolas Pauillac maintained a Buy rating on MedinCell SA (MEDCL – Research Report) on February 26 and set a price ...

Parsippany, New Jersey Thursday, February 27, 2025, 13:00 Hrs [IST] ...

As European markets navigate a landscape marked by cautious optimism amid U.S. trade policy developments and geopolitical efforts, investors are increasingly focused on companies with strong growth ...

The company is leaning on its subcutaneous technology to deliver long-acting options that could prevent patients from cycling through drugs.

The FDA is reviewing risperidone (Uzedy) extended-release injectable suspension for maintenance treatment of adults with ...

The US regulator issued a complete response letter (CRL) for the MedinCell-partnered drug, and the companies haven't been forthcoming on the reasons behind the rejection, saying merely that they ...

It has collaboration agreements with MedinCell S.A.; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel ...

FDA recently announced new safety requirements for DPD screening in cancer patients. Kristine Ashcraft, founder and CEO of ...